Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biogen Idec Inc (BIIB)  
$208.90 6.44 (3.18%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 153,880,000
Market Cap: 32.15(B)
Last Volume: 1,893,879 Avg Vol: 1,345,584
52 Week Range: $190.52 - $318.06
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 500     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 6.9
Insider 6 Months    : 6.9
Insider 3/6 Months : 14.1
Guru Rank Number :  1040
Guru Rank Value     : -1
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 455 455 455 455
Total Buy Value $101,256 $101,256 $101,256 $101,256
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 1,516 1,626 4,819 11,088
Total Sell Value $357,950 $385,230 $1,328,566 $3,190,794
Total People Sold 1 1 2 2
Total Sell Transactions 5 6 9 12
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 2107
  Page 9 of 85  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Guindo Chirfi Head of Glob Prod Strat & Com   •       •      –    2021-06-07 4 AS $440.00 $1,358,280 D/D (3,087) 2,919 -28%     
   Sandrock Alfred Head of Research & Development   •       •      –    2021-06-07 4 AS $440.00 $3,375,680 D/D (7,672) 10,169 -28%     
   Posner Brian S Director   •       •      –    2021-06-04 4 AS $274.17 $98,701 D/D (360) 7,400 -0%     
   Vounatsos Michel Chief Executive Officer   •       •      –    2021-02-12 4 D $278.03 $4,023,928 D/D (14,473) 52,969     -
   Vounatsos Michel Chief Executive Officer   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 16,289 60,194     -
   Galdes Alphonse EVP Pharmaceutical Oper & Tech   •       •      –    2021-02-12 4 D $278.03 $198,791 D/D (715) 4,303     -
   Galdes Alphonse EVP Pharmaceutical Oper & Tech   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 1,573 4,765     -
   Alexander Susan H EVP Chief Legal Off & Corp Sec   •       •      –    2021-02-12 4 D $278.03 $1,083,205 D/D (3,896) 41,576     -
   Alexander Susan H EVP Chief Legal Off & Corp Sec   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 4,355 43,509     -
   Sandrock Alfred EVP, Research & Development   •       •      –    2021-02-12 4 D $278.03 $975,885 D/D (3,510) 17,738     -
   Sandrock Alfred EVP, Research & Development   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 4,454 19,715     -
   Guindo Chirfi EVP Glob. Prod Strat and Comm   •       •      –    2021-02-12 4 D $278.03 $261,348 D/D (940) 6,006     -
   Guindo Chirfi EVP Glob. Prod Strat and Comm   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 3,156 6,946     -
   Kramer Robin SVP, Chief Accounting Officer   •       •      –    2021-02-12 4 D $278.03 $31,973 D/D (115) 591     -
   Kramer Robin SVP, Chief Accounting Officer   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 333 706     -
   Gregory Ginger EVP, Human Resources   •       •      –    2021-02-12 4 D $278.03 $606,661 D/D (2,182) 7,990     -
   Gregory Ginger EVP, Human Resources   •       •      –    2021-02-12 4 OE $0.00 $0 D/D 2,923 9,288     -
   Mantas Jesus B Director   •       •      –    2021-02-09 4 B $267.00 $239,766 D/D 898 2,943 2.39 41%     
   Sandrock Alfred EVP, Research & Development   •       •      –    2021-01-27 4 A $0.00 $0 D/D 3,728 16,794     -
   Alexander Susan H EVP Chief Legal Off & Corp Sec   •       •      –    2021-01-27 4 A $0.00 $0 D/D 4,545 41,117     -
   Vounatsos Michel Chief Executive Officer   •       •      –    2021-01-27 4 A $0.00 $0 D/D 16,343 51,153     -
   Gregory Ginger EVP, Human Resources   •       •      –    2021-01-27 4 A $0.00 $0 D/D 2,558 7,249     -
   Galdes Alphonse EVP Pharmaceutical Oper & Tech   •       •      –    2021-01-27 4 A $0.00 $0 D/D 818 3,445     -
   Kramer Robin VP, Chief Accounting Officer   •       •      –    2020-12-03 4 D $244.09 $5,370 D/D (22) 373     -
   Kramer Robin VP, Chief Accounting Officer   •       •      –    2020-12-03 4 OE $0.00 $0 D/D 74 395     -
  2107 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 85
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us